Yes, somapacitan (Sogroya) is an FDA-approved growth hormone therapy for treating growth hormone deficiency in both adults and children over 2.5 years old. Approved on August 28, 2020, it offers a convenient once-weekly injection, improving adherence and quality of life for patients.
Somapacitan is a growth hormone used to treat growth hormone deficiency in both adults and children aged 2.5 years and older. It belongs to the drug class of growth hormones and is administered as a subcutaneous injection.
Somapacitan works by mimicking the effects of natural growth hormone in the body, which is crucial for growth, metabolism, and muscle development. It helps increase height in children and improve body composition, muscle mass, and overall energy levels in both children and adults with growth hormone deficiency.
Somapacitan is administered as an injection under the skin (subcutaneous). The typical dosage is once a week, and the exact dose is determined by a healthcare provider based on the patient’s specific needs. Important administration guidelines include:
Somapacitan can cause a range of side effects, from common to serious:
Common Side Effects:
Serious Side Effects:
If you experience any serious side effects, you should contact your doctor immediately.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!